Asthma affects more than 300 million persons worldwide, and its prevalence is increasing. Severe asthma affects approximately 5 to 10% of persons with asthma. Patients with severe asthma have poor disease control and frequent exacerbations in spite of treatment with high-dose inhaled…
Currently available biologic therapies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating moderate-to-severe type 2 asthma. However, many patients with type 2 or non–type 2 asthma continue to have symptoms, exacerbations, and reduced lung function. Therefore, new…
Basic science has enriched our understanding of the pathophysiology of severe asthma. Clinical translation of these discoveries has resulted in biologic therapies that target key components of asthma-related disease pathways. For example, identification and validation of biomarkers such as elevated…
RMEI LIGHTNING TALKS
4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far
RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
Allergy & Immunology
Effectiveness of 5-year IBD Provider Online Educational Intervention Program
There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.